Discovery of targeted and personalised interventions.
Target discovery involves the identification and early validation of disease-modifying targets. Biomarkers play an important role in this process as they can be used to indicate disease progression and assess the outcome.
The Institute aims to link genetics, genomics, cell and chemical biology for improved drug target discovery.
UCL Drug Discovery Group
The UCL Translational Research Office (TRO), in partnership with the UCL School of Pharmacy, has established the UCL Drug Discovery Group - a core medicinal chemistry facility. Populated by experienced, industry-background medicinal chemists, the group is based in the UCL School of Pharmacy's established laboratories.
UCL has a number of groups that are involved in omics studies (genomics, proteomics, metabolomics, lipidomics, glycomics) and how these might be applied in clinical practice.
UCL Medical Genomics Laboratory
The UCL Medical Genomics Laboratory has broad interests in the genomics and epigenomics of phenotypic plasticity in health and disease. In addition to genetic variations, the laboratory studies epigenetic variations such as DNA methylation, histone modifications and microRNAs and how they modulate genome function.
UCL Centre for Translational Omics
The UCL Centre for Translational Omics brings together a group of experts in developing and applying omics (genomics, proteomics, metabolomics, lipidomics, glycomics) technologies.